nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—OPRK1—Progesterone—uterine cancer	0.108	0.144	CbGbCtD
Buprenorphine—CYP2A6—Progesterone—uterine cancer	0.0629	0.0836	CbGbCtD
Buprenorphine—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0468	0.0623	CbGbCtD
Buprenorphine—ABCG2—Dactinomycin—uterine cancer	0.0462	0.0614	CbGbCtD
Buprenorphine—CYP3A7—Progesterone—uterine cancer	0.043	0.0572	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.043	0.0572	CbGbCtD
Buprenorphine—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0327	0.0434	CbGbCtD
Buprenorphine—CYP3A5—Progesterone—uterine cancer	0.0323	0.0429	CbGbCtD
Buprenorphine—ABCG2—Carboplatin—uterine cancer	0.031	0.0413	CbGbCtD
Buprenorphine—CYP2C8—Progesterone—uterine cancer	0.031	0.0412	CbGbCtD
Buprenorphine—ABCG2—Etoposide—uterine cancer	0.0261	0.0346	CbGbCtD
Buprenorphine—CYP2C19—Progesterone—uterine cancer	0.026	0.0346	CbGbCtD
Buprenorphine—CYP1A2—Progesterone—uterine cancer	0.024	0.0319	CbGbCtD
Buprenorphine—CYP2C9—Progesterone—uterine cancer	0.0216	0.0288	CbGbCtD
Buprenorphine—ABCB1—Progesterone—uterine cancer	0.021	0.0279	CbGbCtD
Buprenorphine—CYP2D6—Progesterone—uterine cancer	0.0198	0.0263	CbGbCtD
Buprenorphine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.019	0.0252	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—uterine cancer	0.0178	0.0236	CbGbCtD
Buprenorphine—ABCB1—Dactinomycin—uterine cancer	0.0167	0.0221	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—uterine cancer	0.0144	0.0192	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—uterine cancer	0.0139	0.0185	CbGbCtD
Buprenorphine—CYP3A4—Progesterone—uterine cancer	0.0126	0.0167	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—uterine cancer	0.0107	0.0143	CbGbCtD
Buprenorphine—ABCB1—Etoposide—uterine cancer	0.0094	0.0125	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—uterine cancer	0.00641	0.00852	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—uterine cancer	0.00604	0.00803	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—uterine cancer	0.00563	0.00748	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—uterine cancer	0.00384	0.0051	CbGbCtD
Buprenorphine—OPRL1—female reproductive system—uterine cancer	0.0013	0.0801	CbGeAlD
Buprenorphine—UGT1A9—renal system—uterine cancer	0.00106	0.0651	CbGeAlD
Buprenorphine—CYP2C18—uterine cervix—uterine cancer	0.000989	0.0609	CbGeAlD
Buprenorphine—CYP2C18—mammalian vulva—uterine cancer	0.000865	0.0533	CbGeAlD
Buprenorphine—OPRD1—renal system—uterine cancer	0.000837	0.0515	CbGeAlD
Buprenorphine—OPRL1—lymph node—uterine cancer	0.000761	0.0468	CbGeAlD
Buprenorphine—CYP2C18—vagina—uterine cancer	0.00067	0.0412	CbGeAlD
Buprenorphine—OPRK1—female reproductive system—uterine cancer	0.000643	0.0395	CbGeAlD
Buprenorphine—ABCG2—myometrium—uterine cancer	0.000459	0.0282	CbGeAlD
Buprenorphine—CYP2A6—vagina—uterine cancer	0.000443	0.0273	CbGeAlD
Buprenorphine—Naloxone—ESR1—uterine cancer	0.000439	1	CrCbGaD
Buprenorphine—ABCG2—uterine cervix—uterine cancer	0.000357	0.022	CbGeAlD
Buprenorphine—CYP2C8—renal system—uterine cancer	0.000343	0.0211	CbGeAlD
Buprenorphine—ABCG2—decidua—uterine cancer	0.00034	0.0209	CbGeAlD
Buprenorphine—CYP2C8—endometrium—uterine cancer	0.000332	0.0204	CbGeAlD
Buprenorphine—CYP3A5—uterine cervix—uterine cancer	0.000331	0.0204	CbGeAlD
Buprenorphine—ABCG2—endometrium—uterine cancer	0.000323	0.0199	CbGeAlD
Buprenorphine—CYP1A2—renal system—uterine cancer	0.000321	0.0198	CbGeAlD
Buprenorphine—ABCG2—mammalian vulva—uterine cancer	0.000312	0.0192	CbGeAlD
Buprenorphine—CYP3A5—renal system—uterine cancer	0.00031	0.0191	CbGeAlD
Buprenorphine—ABCG2—uterus—uterine cancer	0.000297	0.0183	CbGeAlD
Buprenorphine—CYP2C19—vagina—uterine cancer	0.000285	0.0175	CbGeAlD
Buprenorphine—CYP2C8—female reproductive system—uterine cancer	0.000275	0.0169	CbGeAlD
Buprenorphine—CYP2C8—vagina—uterine cancer	0.000249	0.0153	CbGeAlD
Buprenorphine—CYP2C9—female reproductive system—uterine cancer	0.000244	0.015	CbGeAlD
Buprenorphine—ABCG2—female gonad—uterine cancer	0.000243	0.015	CbGeAlD
Buprenorphine—ABCG2—vagina—uterine cancer	0.000242	0.0149	CbGeAlD
Buprenorphine—CYP3A4—renal system—uterine cancer	0.000233	0.0143	CbGeAlD
Buprenorphine—CYP2D6—renal system—uterine cancer	0.000229	0.0141	CbGeAlD
Buprenorphine—ABCB1—myometrium—uterine cancer	0.000226	0.0139	CbGeAlD
Buprenorphine—CYP3A5—female gonad—uterine cancer	0.000226	0.0139	CbGeAlD
Buprenorphine—CYP3A5—vagina—uterine cancer	0.000224	0.0138	CbGeAlD
Buprenorphine—CYP3A4—female reproductive system—uterine cancer	0.000186	0.0115	CbGeAlD
Buprenorphine—CYP2D6—female reproductive system—uterine cancer	0.000183	0.0113	CbGeAlD
Buprenorphine—ABCB1—epithelium—uterine cancer	0.000177	0.0109	CbGeAlD
Buprenorphine—ABCB1—uterine cervix—uterine cancer	0.000176	0.0108	CbGeAlD
Buprenorphine—Chest pain—Etoposide—uterine cancer	0.000174	0.00089	CcSEcCtD
Buprenorphine—Abdominal pain upper—Epirubicin—uterine cancer	0.000174	0.000889	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Epirubicin—uterine cancer	0.000174	0.000889	CcSEcCtD
Buprenorphine—Affect lability—Doxorubicin—uterine cancer	0.000174	0.000886	CcSEcCtD
Buprenorphine—Migraine—Doxorubicin—uterine cancer	0.000174	0.000886	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000173	0.000884	CcSEcCtD
Buprenorphine—Discomfort—Etoposide—uterine cancer	0.000172	0.00088	CcSEcCtD
Buprenorphine—Breast disorder—Epirubicin—uterine cancer	0.000172	0.000879	CcSEcCtD
Buprenorphine—Nasopharyngitis—Epirubicin—uterine cancer	0.000171	0.00087	CcSEcCtD
Buprenorphine—Face oedema—Doxorubicin—uterine cancer	0.00017	0.000869	CcSEcCtD
Buprenorphine—Hypersensitivity—Dactinomycin—uterine cancer	0.00017	0.000869	CcSEcCtD
Buprenorphine—Confusional state—Etoposide—uterine cancer	0.000169	0.00086	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000168	0.000858	CcSEcCtD
Buprenorphine—Muscular weakness—Epirubicin—uterine cancer	0.000168	0.000858	CcSEcCtD
Buprenorphine—ABCB1—decidua—uterine cancer	0.000168	0.0103	CbGeAlD
Buprenorphine—Anaphylactic shock—Etoposide—uterine cancer	0.000167	0.000853	CcSEcCtD
Buprenorphine—Mood swings—Doxorubicin—uterine cancer	0.000167	0.000853	CcSEcCtD
Buprenorphine—CYP2D6—female gonad—uterine cancer	0.000167	0.0103	CbGeAlD
Buprenorphine—Infection—Etoposide—uterine cancer	0.000166	0.000848	CcSEcCtD
Buprenorphine—Abdominal distension—Epirubicin—uterine cancer	0.000166	0.000847	CcSEcCtD
Buprenorphine—Asthenia—Dactinomycin—uterine cancer	0.000166	0.000846	CcSEcCtD
Buprenorphine—Asthma—Epirubicin—uterine cancer	0.000165	0.000841	CcSEcCtD
Buprenorphine—Dysphagia—Epirubicin—uterine cancer	0.000165	0.000841	CcSEcCtD
Buprenorphine—Influenza—Epirubicin—uterine cancer	0.000165	0.000841	CcSEcCtD
Buprenorphine—ABCB1—renal system—uterine cancer	0.000165	0.0101	CbGeAlD
Buprenorphine—Dehydration—Doxorubicin—uterine cancer	0.000164	0.000837	CcSEcCtD
Buprenorphine—Tachycardia—Etoposide—uterine cancer	0.000163	0.000833	CcSEcCtD
Buprenorphine—Skin disorder—Etoposide—uterine cancer	0.000162	0.000829	CcSEcCtD
Buprenorphine—Dry skin—Doxorubicin—uterine cancer	0.000162	0.000825	CcSEcCtD
Buprenorphine—Hyperhidrosis—Etoposide—uterine cancer	0.000162	0.000825	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000161	0.000822	CcSEcCtD
Buprenorphine—Abdominal pain upper—Doxorubicin—uterine cancer	0.000161	0.000822	CcSEcCtD
Buprenorphine—Angina pectoris—Epirubicin—uterine cancer	0.000161	0.000819	CcSEcCtD
Buprenorphine—Breast disorder—Doxorubicin—uterine cancer	0.000159	0.000814	CcSEcCtD
Buprenorphine—Anorexia—Etoposide—uterine cancer	0.000159	0.000813	CcSEcCtD
Buprenorphine—ABCB1—endometrium—uterine cancer	0.000159	0.00979	CbGeAlD
Buprenorphine—Bronchitis—Epirubicin—uterine cancer	0.000159	0.000809	CcSEcCtD
Buprenorphine—Diarrhoea—Dactinomycin—uterine cancer	0.000158	0.000807	CcSEcCtD
Buprenorphine—Nasopharyngitis—Doxorubicin—uterine cancer	0.000158	0.000805	CcSEcCtD
Buprenorphine—ABCG2—lymph node—uterine cancer	0.000156	0.00962	CbGeAlD
Buprenorphine—Hypotension—Etoposide—uterine cancer	0.000156	0.000797	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000156	0.000794	CcSEcCtD
Buprenorphine—Muscular weakness—Doxorubicin—uterine cancer	0.000156	0.000794	CcSEcCtD
Buprenorphine—ABCB1—mammalian vulva—uterine cancer	0.000154	0.00947	CbGeAlD
Buprenorphine—Abdominal distension—Doxorubicin—uterine cancer	0.000154	0.000784	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000153	0.000782	CcSEcCtD
Buprenorphine—Influenza—Doxorubicin—uterine cancer	0.000153	0.000778	CcSEcCtD
Buprenorphine—Dysphagia—Doxorubicin—uterine cancer	0.000153	0.000778	CcSEcCtD
Buprenorphine—Asthma—Doxorubicin—uterine cancer	0.000153	0.000778	CcSEcCtD
Buprenorphine—Paraesthesia—Etoposide—uterine cancer	0.00015	0.000766	CcSEcCtD
Buprenorphine—Weight decreased—Epirubicin—uterine cancer	0.000149	0.000761	CcSEcCtD
Buprenorphine—Dyspnoea—Etoposide—uterine cancer	0.000149	0.000761	CcSEcCtD
Buprenorphine—Somnolence—Etoposide—uterine cancer	0.000149	0.000759	CcSEcCtD
Buprenorphine—Angina pectoris—Doxorubicin—uterine cancer	0.000149	0.000758	CcSEcCtD
Buprenorphine—Infestation NOS—Epirubicin—uterine cancer	0.000147	0.00075	CcSEcCtD
Buprenorphine—Infestation—Epirubicin—uterine cancer	0.000147	0.00075	CcSEcCtD
Buprenorphine—Vomiting—Dactinomycin—uterine cancer	0.000147	0.00075	CcSEcCtD
Buprenorphine—Bronchitis—Doxorubicin—uterine cancer	0.000147	0.000749	CcSEcCtD
Buprenorphine—ABCB1—uterus—uterine cancer	0.000147	0.00902	CbGeAlD
Buprenorphine—Rash—Dactinomycin—uterine cancer	0.000146	0.000743	CcSEcCtD
Buprenorphine—Decreased appetite—Etoposide—uterine cancer	0.000145	0.000742	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000144	0.000737	CcSEcCtD
Buprenorphine—Fatigue—Etoposide—uterine cancer	0.000144	0.000736	CcSEcCtD
Buprenorphine—Pain—Etoposide—uterine cancer	0.000143	0.00073	CcSEcCtD
Buprenorphine—Constipation—Etoposide—uterine cancer	0.000143	0.00073	CcSEcCtD
Buprenorphine—Urinary tract infection—Epirubicin—uterine cancer	0.000143	0.000729	CcSEcCtD
Buprenorphine—Conjunctivitis—Epirubicin—uterine cancer	0.000143	0.000729	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000142	0.000723	CcSEcCtD
Buprenorphine—Sweating—Epirubicin—uterine cancer	0.000141	0.000719	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000139	0.000709	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—uterine cancer	0.000138	0.000704	CcSEcCtD
Buprenorphine—Sinusitis—Epirubicin—uterine cancer	0.000138	0.000704	CcSEcCtD
Buprenorphine—Feeling abnormal—Etoposide—uterine cancer	0.000138	0.000703	CcSEcCtD
Buprenorphine—Nausea—Dactinomycin—uterine cancer	0.000137	0.0007	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Etoposide—uterine cancer	0.000137	0.000698	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—uterine cancer	0.000136	0.000694	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—uterine cancer	0.000136	0.000694	CcSEcCtD
Buprenorphine—Bradycardia—Epirubicin—uterine cancer	0.000134	0.000685	CcSEcCtD
Buprenorphine—Urticaria—Etoposide—uterine cancer	0.000133	0.000678	CcSEcCtD
Buprenorphine—Rhinitis—Epirubicin—uterine cancer	0.000132	0.000675	CcSEcCtD
Buprenorphine—Body temperature increased—Etoposide—uterine cancer	0.000132	0.000675	CcSEcCtD
Buprenorphine—Abdominal pain—Etoposide—uterine cancer	0.000132	0.000675	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—uterine cancer	0.000132	0.000675	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—uterine cancer	0.000132	0.000675	CcSEcCtD
Buprenorphine—ABCB1—female reproductive system—uterine cancer	0.000132	0.00811	CbGeAlD
Buprenorphine—Hypoaesthesia—Epirubicin—uterine cancer	0.000131	0.00067	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—uterine cancer	0.000131	0.000668	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—uterine cancer	0.00013	0.000665	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—uterine cancer	0.00013	0.000665	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—uterine cancer	0.00013	0.000663	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—uterine cancer	0.00013	0.000662	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—uterine cancer	0.000129	0.00066	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000129	0.000656	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—uterine cancer	0.000128	0.000651	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—uterine cancer	0.000127	0.000649	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—uterine cancer	0.000124	0.000634	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—uterine cancer	0.000123	0.000629	CcSEcCtD
Buprenorphine—Hypersensitivity—Etoposide—uterine cancer	0.000123	0.000629	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—uterine cancer	0.000123	0.000628	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—uterine cancer	0.000122	0.000625	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—uterine cancer	0.000122	0.000625	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—uterine cancer	0.000122	0.000625	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—uterine cancer	0.000121	0.00062	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—uterine cancer	0.000121	0.000618	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000121	0.000615	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—uterine cancer	0.00012	0.000614	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—uterine cancer	0.00012	0.000612	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—uterine cancer	0.00012	0.000612	CcSEcCtD
Buprenorphine—ABCB1—female gonad—uterine cancer	0.00012	0.00738	CbGeAlD
Buprenorphine—Angiopathy—Epirubicin—uterine cancer	0.00012	0.000611	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—uterine cancer	0.00012	0.000611	CcSEcCtD
Buprenorphine—ABCB1—vagina—uterine cancer	0.000119	0.00734	CbGeAlD
Buprenorphine—Immune system disorder—Epirubicin—uterine cancer	0.000119	0.000608	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—uterine cancer	0.000119	0.000607	CcSEcCtD
Buprenorphine—Chills—Epirubicin—uterine cancer	0.000118	0.000604	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—uterine cancer	0.000118	0.000604	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—uterine cancer	0.000118	0.0006	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—uterine cancer	0.000116	0.00059	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—uterine cancer	0.000115	0.000586	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—uterine cancer	0.000115	0.000586	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—uterine cancer	0.000114	0.000584	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—uterine cancer	0.000114	0.000582	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—uterine cancer	0.000114	0.000581	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—uterine cancer	0.000113	0.000578	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—uterine cancer	0.000113	0.000578	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—uterine cancer	0.000113	0.000578	CcSEcCtD
Buprenorphine—Tension—Epirubicin—uterine cancer	0.000113	0.000575	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—uterine cancer	0.000112	0.000574	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—uterine cancer	0.000112	0.000569	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—uterine cancer	0.000111	0.000567	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—uterine cancer	0.000111	0.000565	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—uterine cancer	0.000111	0.000564	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—uterine cancer	0.00011	0.000564	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—uterine cancer	0.00011	0.000563	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—uterine cancer	0.00011	0.000561	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—uterine cancer	0.00011	0.000559	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—uterine cancer	0.000108	0.000552	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—uterine cancer	0.000107	0.000546	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—uterine cancer	0.000107	0.000544	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—uterine cancer	0.000106	0.000543	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—uterine cancer	0.000106	0.000542	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—uterine cancer	0.000106	0.000542	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—uterine cancer	0.000106	0.000539	CcSEcCtD
Buprenorphine—Rash—Etoposide—uterine cancer	0.000105	0.000538	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—uterine cancer	0.000105	0.000538	CcSEcCtD
Buprenorphine—Headache—Etoposide—uterine cancer	0.000105	0.000535	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—uterine cancer	0.000105	0.000534	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—uterine cancer	0.000104	0.000532	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—uterine cancer	0.000104	0.000531	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—uterine cancer	0.000104	0.000529	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—uterine cancer	0.000103	0.000527	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—uterine cancer	0.000103	0.000527	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—uterine cancer	0.000103	0.000526	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—uterine cancer	0.000103	0.000525	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—uterine cancer	0.000102	0.000521	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—uterine cancer	0.000101	0.000518	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—uterine cancer	0.000101	0.000515	CcSEcCtD
Buprenorphine—Cough—Epirubicin—uterine cancer	0.0001	0.000511	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—uterine cancer	0.0001	0.000511	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—uterine cancer	9.95e-05	0.000508	CcSEcCtD
Buprenorphine—Nausea—Etoposide—uterine cancer	9.93e-05	0.000507	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—uterine cancer	9.92e-05	0.000506	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—uterine cancer	9.86e-05	0.000503	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—uterine cancer	9.78e-05	0.000499	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—uterine cancer	9.78e-05	0.000499	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—uterine cancer	9.78e-05	0.000499	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—uterine cancer	9.77e-05	0.000498	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—uterine cancer	9.74e-05	0.000497	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	9.71e-05	0.000496	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—uterine cancer	9.66e-05	0.000493	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—uterine cancer	9.58e-05	0.000489	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—uterine cancer	9.56e-05	0.000488	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—uterine cancer	9.55e-05	0.000487	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—uterine cancer	9.53e-05	0.000486	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—uterine cancer	9.45e-05	0.000482	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—uterine cancer	9.39e-05	0.000479	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—uterine cancer	9.37e-05	0.000478	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—uterine cancer	9.37e-05	0.000478	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—uterine cancer	9.34e-05	0.000477	CcSEcCtD
Buprenorphine—Infection—Epirubicin—uterine cancer	9.31e-05	0.000475	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—uterine cancer	9.27e-05	0.000473	CcSEcCtD
Buprenorphine—Shock—Epirubicin—uterine cancer	9.22e-05	0.000471	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—uterine cancer	9.21e-05	0.00047	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—uterine cancer	9.19e-05	0.000469	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—uterine cancer	9.18e-05	0.000468	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—uterine cancer	9.15e-05	0.000467	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—uterine cancer	9.1e-05	0.000465	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—uterine cancer	9.06e-05	0.000462	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—uterine cancer	9.05e-05	0.000462	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—uterine cancer	9.05e-05	0.000462	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—uterine cancer	9.05e-05	0.000462	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—uterine cancer	9.02e-05	0.00046	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	8.99e-05	0.000459	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—uterine cancer	8.94e-05	0.000456	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—uterine cancer	8.94e-05	0.000456	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—uterine cancer	8.85e-05	0.000452	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—uterine cancer	8.76e-05	0.000447	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—uterine cancer	8.75e-05	0.000446	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—uterine cancer	8.67e-05	0.000443	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—uterine cancer	8.67e-05	0.000443	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—uterine cancer	8.62e-05	0.00044	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—uterine cancer	8.54e-05	0.000436	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—uterine cancer	8.53e-05	0.000435	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—uterine cancer	8.51e-05	0.000434	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—uterine cancer	8.48e-05	0.000433	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—uterine cancer	8.46e-05	0.000432	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—uterine cancer	8.42e-05	0.00043	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—uterine cancer	8.42e-05	0.00043	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—uterine cancer	8.38e-05	0.000428	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—uterine cancer	8.36e-05	0.000426	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—uterine cancer	8.33e-05	0.000425	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—uterine cancer	8.27e-05	0.000422	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—uterine cancer	8.25e-05	0.000421	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—uterine cancer	8.15e-05	0.000416	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—uterine cancer	8.1e-05	0.000414	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—uterine cancer	8.09e-05	0.000413	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—uterine cancer	8.08e-05	0.000412	CcSEcCtD
Buprenorphine—Pain—Epirubicin—uterine cancer	8.02e-05	0.000409	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—uterine cancer	8.02e-05	0.000409	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	7.9e-05	0.000403	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—uterine cancer	7.84e-05	0.0004	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—uterine cancer	7.79e-05	0.000397	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—uterine cancer	7.73e-05	0.000395	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—uterine cancer	7.72e-05	0.000394	CcSEcCtD
Buprenorphine—ABCB1—lymph node—uterine cancer	7.71e-05	0.00475	CbGeAlD
Buprenorphine—Somnolence—Doxorubicin—uterine cancer	7.71e-05	0.000393	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—uterine cancer	7.67e-05	0.000391	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—uterine cancer	7.63e-05	0.00039	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—uterine cancer	7.54e-05	0.000385	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—uterine cancer	7.49e-05	0.000382	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—uterine cancer	7.48e-05	0.000382	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—uterine cancer	7.45e-05	0.00038	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—uterine cancer	7.42e-05	0.000378	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—uterine cancer	7.42e-05	0.000378	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—uterine cancer	7.41e-05	0.000378	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—uterine cancer	7.41e-05	0.000378	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—uterine cancer	7.15e-05	0.000365	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—uterine cancer	7.09e-05	0.000362	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—uterine cancer	6.91e-05	0.000352	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—uterine cancer	6.89e-05	0.000352	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—uterine cancer	6.86e-05	0.00035	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—uterine cancer	6.86e-05	0.00035	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—uterine cancer	6.73e-05	0.000343	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—uterine cancer	6.63e-05	0.000338	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—uterine cancer	6.41e-05	0.000327	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—uterine cancer	6.39e-05	0.000326	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—uterine cancer	6.22e-05	0.000318	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—uterine cancer	6.2e-05	0.000316	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—uterine cancer	6.14e-05	0.000313	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—uterine cancer	5.96e-05	0.000304	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—uterine cancer	5.93e-05	0.000303	CcSEcCtD
Buprenorphine—Rash—Epirubicin—uterine cancer	5.91e-05	0.000302	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—uterine cancer	5.9e-05	0.000301	CcSEcCtD
Buprenorphine—Headache—Epirubicin—uterine cancer	5.87e-05	0.0003	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—uterine cancer	5.74e-05	0.000293	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—uterine cancer	5.57e-05	0.000284	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—uterine cancer	5.51e-05	0.000281	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—uterine cancer	5.47e-05	0.000279	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—uterine cancer	5.46e-05	0.000279	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—uterine cancer	5.43e-05	0.000277	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—uterine cancer	5.15e-05	0.000263	CcSEcCtD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.42e-05	0.000405	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—POLD1—uterine cancer	1.42e-05	0.000405	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FBXW7—uterine cancer	1.41e-05	0.000404	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.41e-05	0.000402	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SOCS3—uterine cancer	1.37e-05	0.000391	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—RRM2—uterine cancer	1.36e-05	0.00039	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SMAD3—uterine cancer	1.36e-05	0.00039	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.35e-05	0.000386	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.34e-05	0.000383	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.34e-05	0.000383	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.33e-05	0.000379	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—DCN—uterine cancer	1.32e-05	0.000379	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCL8—uterine cancer	1.31e-05	0.000375	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN2B—uterine cancer	1.31e-05	0.000374	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—FGFR2—uterine cancer	1.3e-05	0.000372	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—STK11—uterine cancer	1.28e-05	0.000366	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CYP19A1—uterine cancer	1.28e-05	0.000366	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IGF1R—uterine cancer	1.27e-05	0.000364	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CYP19A1—uterine cancer	1.27e-05	0.000363	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—STK11—uterine cancer	1.27e-05	0.000363	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCL8—uterine cancer	1.27e-05	0.000362	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—POLD1—uterine cancer	1.26e-05	0.000362	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.26e-05	0.000359	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—STAR—uterine cancer	1.26e-05	0.000359	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—KRAS—uterine cancer	1.25e-05	0.000358	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP11A1—uterine cancer	1.25e-05	0.000357	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.24e-05	0.000355	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—POLD1—uterine cancer	1.23e-05	0.000353	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STK11—uterine cancer	1.23e-05	0.000353	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL2—uterine cancer	1.23e-05	0.000351	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SMAD3—uterine cancer	1.2e-05	0.000342	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.2e-05	0.000342	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.18e-05	0.000338	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—RRM2—uterine cancer	1.18e-05	0.000338	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKR1C3—uterine cancer	1.18e-05	0.000337	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—STK11—uterine cancer	1.16e-05	0.000333	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CYP19A1—uterine cancer	1.16e-05	0.000333	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—POLD1—uterine cancer	1.16e-05	0.000333	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SOCS3—uterine cancer	1.16e-05	0.000331	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKR1C1—uterine cancer	1.15e-05	0.00033	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—POLD1—uterine cancer	1.15e-05	0.00033	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PIK3CA—uterine cancer	1.15e-05	0.000329	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCL8—uterine cancer	1.15e-05	0.000329	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—DCN—uterine cancer	1.15e-05	0.000328	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FGFR2—uterine cancer	1.14e-05	0.000326	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—MTHFR—uterine cancer	1.13e-05	0.000324	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—uterine cancer	1.11e-05	0.000318	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ESR1—uterine cancer	1.11e-05	0.000318	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN2B—uterine cancer	1.11e-05	0.000316	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.1e-05	0.000314	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.09e-05	0.000311	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.08e-05	0.000309	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.08e-05	0.000308	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1R—uterine cancer	1.07e-05	0.000307	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCL8—uterine cancer	1.07e-05	0.000306	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HRAS—uterine cancer	1.06e-05	0.000304	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.06e-05	0.000304	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—RRM2—uterine cancer	1.05e-05	0.000302	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—NRAS—uterine cancer	1.05e-05	0.000301	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—RRM2—uterine cancer	1.03e-05	0.000294	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—DCN—uterine cancer	1.02e-05	0.000293	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.02e-05	0.000292	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SMAD3—uterine cancer	1.01e-05	0.000289	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1e-05	0.000286	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—DCN—uterine cancer	9.99e-06	0.000286	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—POLD1—uterine cancer	9.86e-06	0.000282	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL2—uterine cancer	9.79e-06	0.00028	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ESR1—uterine cancer	9.76e-06	0.000279	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL8—uterine cancer	9.71e-06	0.000278	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—RRM2—uterine cancer	9.7e-06	0.000277	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—STAR—uterine cancer	9.69e-06	0.000277	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.69e-06	0.000277	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP11A1—uterine cancer	9.64e-06	0.000276	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FGFR2—uterine cancer	9.64e-06	0.000276	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—MTHFR—uterine cancer	9.63e-06	0.000275	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—RRM2—uterine cancer	9.61e-06	0.000275	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—MTHFR—uterine cancer	9.54e-06	0.000273	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—DCN—uterine cancer	9.42e-06	0.000269	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP11A1—uterine cancer	9.41e-06	0.000269	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AKT1—uterine cancer	9.4e-06	0.000269	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—DCN—uterine cancer	9.33e-06	0.000267	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—NRAS—uterine cancer	9.22e-06	0.000264	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKR1C1—uterine cancer	9.22e-06	0.000264	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—STK11—uterine cancer	9.18e-06	0.000262	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP19A1—uterine cancer	9.18e-06	0.000262	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PIK3CA—uterine cancer	9.16e-06	0.000262	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKR1C3—uterine cancer	9.11e-06	0.00026	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—KRAS—uterine cancer	9.05e-06	0.000259	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.97e-06	0.000257	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKR1C3—uterine cancer	8.89e-06	0.000254	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP11A1—uterine cancer	8.87e-06	0.000254	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP11A1—uterine cancer	8.79e-06	0.000251	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—MTHFR—uterine cancer	8.75e-06	0.00025	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL2—uterine cancer	8.59e-06	0.000246	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKR1C3—uterine cancer	8.38e-06	0.00024	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—uterine cancer	8.32e-06	0.000238	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKR1C3—uterine cancer	8.3e-06	0.000237	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ESR1—uterine cancer	8.24e-06	0.000236	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—RRM2—uterine cancer	8.22e-06	0.000235	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—uterine cancer	8.17e-06	0.000233	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—uterine cancer	8.03e-06	0.00023	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTEN—uterine cancer	7.98e-06	0.000228	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—DCN—uterine cancer	7.98e-06	0.000228	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—STK11—uterine cancer	7.95e-06	0.000227	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP19A1—uterine cancer	7.95e-06	0.000227	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—uterine cancer	7.94e-06	0.000227	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—NRAS—uterine cancer	7.79e-06	0.000223	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—uterine cancer	7.74e-06	0.000221	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—uterine cancer	7.69e-06	0.00022	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—EP300—uterine cancer	7.61e-06	0.000218	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—POLD1—uterine cancer	7.61e-06	0.000217	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1B—uterine cancer	7.56e-06	0.000216	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP11A1—uterine cancer	7.51e-06	0.000215	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—uterine cancer	7.48e-06	0.000214	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.46e-06	0.000213	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—uterine cancer	7.29e-06	0.000209	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL2—uterine cancer	7.26e-06	0.000208	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—uterine cancer	7.16e-06	0.000205	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CTNNB1—uterine cancer	7.14e-06	0.000204	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.12e-06	0.000203	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.11e-06	0.000203	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKR1C3—uterine cancer	7.1e-06	0.000203	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—STK11—uterine cancer	7.1e-06	0.000203	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP19A1—uterine cancer	7.1e-06	0.000203	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—uterine cancer	6.96e-06	0.000199	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—STK11—uterine cancer	6.93e-06	0.000198	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP19A1—uterine cancer	6.93e-06	0.000198	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—MTHFR—uterine cancer	6.9e-06	0.000197	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—uterine cancer	6.79e-06	0.000194	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—uterine cancer	6.79e-06	0.000194	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—uterine cancer	6.79e-06	0.000194	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—uterine cancer	6.75e-06	0.000193	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—uterine cancer	6.71e-06	0.000192	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.66e-06	0.00019	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EP300—uterine cancer	6.64e-06	0.00019	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1B—uterine cancer	6.63e-06	0.00019	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—uterine cancer	6.56e-06	0.000188	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—STK11—uterine cancer	6.53e-06	0.000187	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP19A1—uterine cancer	6.53e-06	0.000187	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP19A1—uterine cancer	6.47e-06	0.000185	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—STK11—uterine cancer	6.47e-06	0.000185	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.35e-06	0.000182	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—RRM2—uterine cancer	6.34e-06	0.000181	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—uterine cancer	6.31e-06	0.00018	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—uterine cancer	6.29e-06	0.00018	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CTNNB1—uterine cancer	6.26e-06	0.000179	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—uterine cancer	6.21e-06	0.000178	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—uterine cancer	6.16e-06	0.000176	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—DCN—uterine cancer	6.16e-06	0.000176	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—uterine cancer	6.11e-06	0.000175	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.07e-06	0.000174	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—uterine cancer	6.05e-06	0.000173	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—uterine cancer	6.02e-06	0.000172	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—uterine cancer	5.97e-06	0.000171	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—uterine cancer	5.96e-06	0.00017	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—uterine cancer	5.82e-06	0.000167	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.8e-06	0.000166	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.79e-06	0.000166	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—uterine cancer	5.74e-06	0.000164	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—uterine cancer	5.7e-06	0.000163	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—uterine cancer	5.63e-06	0.000161	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—uterine cancer	5.6e-06	0.00016	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—uterine cancer	5.54e-06	0.000159	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—STK11—uterine cancer	5.53e-06	0.000158	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP19A1—uterine cancer	5.53e-06	0.000158	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—uterine cancer	5.52e-06	0.000158	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.48e-06	0.000157	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—uterine cancer	5.45e-06	0.000156	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—uterine cancer	5.36e-06	0.000153	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—uterine cancer	5.35e-06	0.000153	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—uterine cancer	5.33e-06	0.000152	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—uterine cancer	5.31e-06	0.000152	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—uterine cancer	5.29e-06	0.000151	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.26e-06	0.000151	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—uterine cancer	5.2e-06	0.000149	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.19e-06	0.000148	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—uterine cancer	5.16e-06	0.000148	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—uterine cancer	5.11e-06	0.000146	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—uterine cancer	5.06e-06	0.000145	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—uterine cancer	5.03e-06	0.000144	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.95e-06	0.000142	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—uterine cancer	4.92e-06	0.000141	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—uterine cancer	4.91e-06	0.00014	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—uterine cancer	4.9e-06	0.00014	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—uterine cancer	4.87e-06	0.000139	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—uterine cancer	4.86e-06	0.000139	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—uterine cancer	4.75e-06	0.000136	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.7e-06	0.000134	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—uterine cancer	4.69e-06	0.000134	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—uterine cancer	4.66e-06	0.000133	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—uterine cancer	4.64e-06	0.000133	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—uterine cancer	4.6e-06	0.000132	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—uterine cancer	4.6e-06	0.000132	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—uterine cancer	4.54e-06	0.00013	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—uterine cancer	4.45e-06	0.000127	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—uterine cancer	4.31e-06	0.000123	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.28e-06	0.000123	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—STK11—uterine cancer	4.27e-06	0.000122	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.27e-06	0.000122	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—uterine cancer	4.17e-06	0.000119	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—uterine cancer	4.15e-06	0.000119	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—uterine cancer	4.01e-06	0.000115	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—uterine cancer	3.99e-06	0.000114	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—uterine cancer	3.96e-06	0.000113	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—uterine cancer	3.84e-06	0.00011	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—uterine cancer	3.78e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—uterine cancer	3.74e-06	0.000107	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.66e-06	0.000105	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—uterine cancer	3.66e-06	0.000105	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—uterine cancer	3.64e-06	0.000104	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—uterine cancer	3.64e-06	0.000104	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—uterine cancer	3.52e-06	0.000101	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—uterine cancer	3.52e-06	0.000101	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—uterine cancer	3.43e-06	9.81e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—uterine cancer	3.37e-06	9.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—uterine cancer	3.32e-06	9.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—uterine cancer	3.21e-06	9.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—uterine cancer	3.17e-06	9.06e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—uterine cancer	3.09e-06	8.82e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—uterine cancer	3.06e-06	8.75e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—uterine cancer	2.97e-06	8.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—uterine cancer	2.97e-06	8.48e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—uterine cancer	2.9e-06	8.28e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—uterine cancer	2.83e-06	8.09e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—uterine cancer	2.8e-06	8.02e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—uterine cancer	2.76e-06	7.89e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—uterine cancer	2.73e-06	7.8e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.71e-06	7.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—uterine cancer	2.7e-06	7.73e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—uterine cancer	2.6e-06	7.44e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—uterine cancer	2.58e-06	7.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—uterine cancer	2.34e-06	6.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—uterine cancer	2.31e-06	6.61e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—uterine cancer	2.21e-06	6.32e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—uterine cancer	2.2e-06	6.3e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.09e-06	5.98e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—uterine cancer	2.04e-06	5.84e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.92e-06	5.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—uterine cancer	1.92e-06	5.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.91e-06	5.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—uterine cancer	1.78e-06	5.1e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—uterine cancer	1.71e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—uterine cancer	1.7e-06	4.86e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—uterine cancer	1.67e-06	4.77e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.63e-06	4.66e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—uterine cancer	1.57e-06	4.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—uterine cancer	1.56e-06	4.46e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—uterine cancer	1.33e-06	3.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.26e-06	3.6e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—uterine cancer	1.03e-06	2.94e-05	CbGpPWpGaD
